Akari Therapeutics Plc

2.50 USD
+0.26 (+11.61%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Akari Therapeutics Plc stock is down -5.66% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 February’s closed higher than January.

About Akari Therapeutics Plc

Akari Therapeutics, Plc focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.